ArticleJournal of Korean medical science2026
EGFR and Its Ligands in Idiopathic Pulmonary Fibrosis: Predicting Clinical Outcomes and Molecular Endotyping Through In-Depth Analysis.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe dysregulation of alveolar epithelial cells has been proposed as the cause of idiopathic pulmonary fibrosis (IPF) due to abnormal activation of epidermal growth factor receptor (EGFR). However, the ways of interaction with EGFR ligands including amphiregulin (AREG), epidermal growth factor (EGF), transforming growth factor (TGF)-α and heparin-binding EGF have not been revealed. The aim of the present study was to investigate the diagnostic and prognostic significance of EGFR and its ligands in IPF.
methodsEGFR and its ligands were quantified by enzyme-linked immunosorbent assay in bronchoalveolar lavage (BAL) fluids and serum from 131 patients with IPF and 52 normal controls (NCs). Mortality risk was evaluated using Cox proportional hazards models. Cluster analysis based on EGFR and its ligands was conducted using both hierarchical and K-means clustering methods.
resultsThe patients exhibited significantly higher levels of EGFR, AREG, EGF, and TGF-α compared to NCs. The threshold values for AREG, EGF and TGF-α were determined to be 12.2 pg/mL, 6.3 pg/mL and 5.2 pg/mL, respectively, for the two groups. The sensitivities were 79.83%, 88.24%, and 56.30%, and the specificities were 81.82%, 31.82%, and 63.64% to diagnose IPF, respectively. The mortality rate was significantly higher in IPF patients with low levels compared to those with high levels of EGFR and EGF on Cox analysis. Four distinct clusters were identified based on the levels of EGFR and its ligands in BAL fluids. C3 group (n = 7), which exhibited the highest levels of TGF-α, AREG and EGFR, showed the highest risk of mortality, whereas the C2 group (n = 40), with the highest level of EGF and the intermediate levels of AREG, EGFR, and TGF-α, had the lowest risk.
conclusionThe diverse effects of EGFR on mortality may depend on balance of TGF-α and EGF. Therefore, a comprehensive analysis of EGFR and its ligands could help predict molecular endotypes and clinical outcomes for IPF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.